Key Drivers
- Strong liquidity
- High reported margins
- Accounting volatility
AIAI Summary
Zevra's strategic shift to a single commercial product (MIPLYFFA) turns the story from pipeline binary risk to an execution-and-reimbursement play where the stock hinges on repeatable U.S. script growth, Medicare Part D/ payer expansion, and successful European commercialization. If management sustains multi‑quarter prescription momentum and normalizes rebate/true‑ups, the company can convert high gross margins and ample near‑term liquidity into durable cash flow; conversely, any reimbursement setbacks, governance/legal overhangs, or uptake stalls would sharply impair valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High reported margins
- •Accounting volatility
ZVRA has very strong liquidity and eye‑popping reported margins with low valuation multiples, but significant operating volatility, large non‑operating balances and deeply negative retained earnings require investigation before relying on headline profitability.
Price Behavior
Key Price Behavior Insights:
- •Below last-month SMA
- •Event-driven spike
- •Clustered support
Price is short-term bearish, trading below its last-month SMA and recent close after an event-driven spike to $11.06 that quickly reversed into the $9 area, with clustered support near $8.79–$8.98 limiting further downside.
Sharp spike to $11.06 on 2026-03-10 followed by rapid pullback into ~$9.0 over 2026-03-11–03-12
Sentiment & News
Key News Insights:
- •Rapid Miplyffa uptake
- •SDX portfolio sale
- •Discounted multiples
Zevra's March momentum from Miplyffa drove FY25 revenue to $106.5M (+350% YoY) and GAAP EPS $1.40, boosting the stock while valuation discounts and the $50M SDX sale/CFO equity award highlight questions about sustainability.
Near-term revenue and stock support are likely, but sustainable upside hinges on continued Miplyffa adoption and repeatable earnings
Similar Companies in Healthcare
Other companies in the same sector with AI ratings